[
    {
        "other_ids": [],
        "amendment_date": null,
        "keywords": null,
        "dcp_id": null,
        "interventional_model": "Parallel",
        "lead_org": "Rubius Therapeutics",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Signed written informed consent obtained prior to study procedures"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Patients \u226518 years with an ECOG 0 or 1 (Parts 1, 2 and 4) or 0-2 (Part 3)."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "Relapsed/Refractory (R/R) or locally advanced, unresectable solid tumor for which no standard therapy exists (Parts 1, 2 and 4), or for which the patient is ineligible or has declined standard therapy or R/R, cytologically confirmed AML (Part 3)."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "Disease must be measurable per Response Evaluation Criteria"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "The shorter of 28 days or 5 half-lives must have elapsed since the completion of prior therapy, before initiation of study treatment."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "Adequate Organ Function and Blood Cell Counts (Parts 1, 2, and 4) as defined by the protocol:"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 6,
                    "description": "GFR \u2265 50 mL/min/1.73,"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 7,
                    "description": "AST and ALT \u2264 3 \u00d7 the ULN and total bilirubin \u2264 1.5 \u00d7 ULN, in the absence of cancer within the liver"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 8,
                    "description": "Or AST and ALT \u2264 5 \u00d7 ULN and total bilirubin \u2264 3 \u00d7 ULN, in the setting of primary or metastatic liver tumors."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 9,
                    "description": "ANC \u2265 1 \u00d7 10^3/\u03bcL without myeloid growth factor support for at least one week prior to enrollment"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 10,
                    "description": "Platelet count \u2265 75 \u00d7 10^3/\u03bcL"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 11,
                    "description": "Hemoglobin should be \u2265 9 g/dL without red blood cell transfusion for at least one week"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 12,
                    "description": "Patients must have LVEF \u2265 45%"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 13,
                    "description": "Patients enrolling into Part 2 of the study must be diagnosed with NSCLC, RCC, or anal cancers"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 14,
                    "description": "Patients enrolling into Part 4 must be diagnosed with NSCLC or RCC"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 15,
                    "description": "Patients enrolling into either Part 2 or 4 must have 2 or fewer prior treatment regimens. If patient received a prior PD-1/PD-L1-containing regimen, a prior response is required."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 16,
                    "description": "Primary central nervous system (CNS) malignancy or CNS involvement, unless asymptomatic, previously treated, and stable without steroids (Parts 1, 2 and 4) or known CNS leukemia (Part 3)."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 17,
                    "description": "Known hypersensitivity to any component of study treatment or excipients."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 18,
                    "description": "Positive antibody screen using institution's standard type and screen test."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 19,
                    "description": "Clinically significant, active and uncontrolled infection, including human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV)."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 20,
                    "description": "Clinically significant coagulopathy, uncontrolled hypertension or autoimmune hemolytic anemia"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 21,
                    "description": "Class III or IV cardiomyopathy per the New York Heart Association criteria"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 22,
                    "description": "Leukemic blast count \u2265 25 x 10^3/\u00b5L (Part 3)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 23,
                    "description": "Concomitant conditions requiring active immunosuppression"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 24,
                    "description": "History of clinically significant Grade 3 or higher immune related Adverse Event (irAE)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 25,
                    "description": "Prior malignancy within the past 3 years, with protocol specified exceptions"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 26,
                    "description": "History of severe hypersensitivity to a PD-1/PD-L1 blocking Ab unless previously rechallenged successfully (Part 4)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 27,
                    "description": "Current noninfectious pneumonitis or a history of radiation pneumonitis or pneumonitis that required steroids, or Grade 2 or greater immune related pneumonitis, hepatitis, hypophysitis, or other endocrinopathy (Part 4)"
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ACTUAL",
        "detail_description": "This is a Phase 1/2, open label, multicenter, multidose, first-in-human (FIH) dose escalation\r\n      and expansion study to determine the safety and tolerability, recommended phase 2 dose and\r\n      optimal dosing interval, pharmacology, and antitumor activity of RTX-240 in adult patients\r\n      with relapsed/refractory (R/R) or locally advanced solid tumors (Phase 1/2) or R/R acute\r\n      myeloid leukemia (Phase 1 only), and RTX-240 in combination with pembrolizumab in adult\r\n      patients with R/R or locally advanced solid tumors (Phase 1 only). RTX-240 is a cellular\r\n      therapy that co-expresses 4-1BBL and IL-15TP, a fusion of IL-15 and IL-15 receptor alpha,\r\n      with the goal of stimulating the innate and adaptive immune systems for the treatment of\r\n      cancer. The study includes a monotherapy dose escalation phase (Phase 1) followed by an\r\n      expansion phase (Phase 2) in specified tumor types.",
        "official_title": "Phase 1/2 Study of RTX-240 Monotherapy and in Combination With Pembrolizumab",
        "_phase_sort_order": 3,
        "collaborators": [],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "Up to 38 months",
                "name": "Anti-tumor activity of study treatment measured by clinical benefit rate (CBR) (% of patients who achieve CR, PR or stable disease [SD])",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 38 months",
                "name": "Anti-tumor activity of study treatment measured by duration of response (DoR)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 38 months",
                "name": "Anti-Tumor activity of study treatment Measured by Objective Response Rate (ORR)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 38 months",
                "name": "Anti-tumor activity of study treatment measured by overall survival (OS)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 38 months",
                "name": "Anti-tumor activity of study treatment measured by progression free survival (PFS)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 38 months",
                "name": "Anti-tumor activity of study treatment measured by time to progression (TTP)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 38 months",
                "name": "Anti-tumor activity of study treatment measured by time to response (TTR).",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Assessed From the 1st dose of RTX-240 until 30 days after last of study treatment",
                "name": "Determination of the Immunogenicity of study treatment Measured by the incidence of antibodies to RTX-240",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 38 months",
                "name": "Dose limiting toxicities (DLTs) of study treatment as determined by incidence and severity of adverse events (AEs)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Assessed From the 1st dose of RTX-240 until 30 days after last of study treatment",
                "name": "PK of study treatment as measured by detection of the number of cells positive for both 4-1BBL and IL-15 using flow cytometry.",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 38 months",
                "name": "Proportion of AML patients with CR, CR with incomplete recovery (CRi), morphologic leukemia-free state, or PR",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 38 months",
                "name": "Safety Assessment: Measured by incidence of Treatment Emergent Adverse Events (TEAEs)",
                "description": null,
                "type_code": "PRIMARY"
            }
        ],
        "phase": "I_II",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 4,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT04372706",
        "biomarkers": [],
        "classification_code": null,
        "current_trial_status_date": "2022-11-30",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Recurrent Solid Tumor",
                    "Relapsed Malignant Solid Neoplasm",
                    "Recurrent Malignant Solid Neoplasm",
                    "Relapsed Solid Neoplasm",
                    "Relapsed Solid Tumor",
                    "Recurrent Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127153",
                "name": "Recurrent Malignant Solid Tumor",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C132146",
                    "C4813"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Locally Advanced Solid Tumor",
                    "Locally Advanced Malignant Solid Neoplasm",
                    "Locally Advanced Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C133093",
                "name": "Locally Advanced Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C8524",
                    "C127155"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C133737",
                "name": "Refractory Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C132146",
                    "C120186"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Unresectable Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C148036",
                "name": "Unresectable Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C127156",
                    "C27359",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Tumor, malignant, NOS",
                    "Malignancy",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease",
                    "Malignant Growth",
                    "CA",
                    "Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Solid Neoplasm",
                    "Metastatic Malignant Solid Neoplasm",
                    "Metastatic Solid Tumor"
                ],
                "nci_thesaurus_concept_id": "C127155",
                "name": "Metastatic Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Locally Advanced Cancer",
                    "regional cancer",
                    "Locally advanced",
                    "Locally Metastatic Malignant Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C8524",
                "name": "Locally Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Solid Neoplasm",
                    "Solid Tumour",
                    "Solid tumor, NOS"
                ],
                "nci_thesaurus_concept_id": "C9292",
                "name": "Solid Tumor",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C132146",
                "name": "Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Cancer",
                    "Secondary Malignancy"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36255",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Diseases",
                    "Disease",
                    "Diseases and Disorders",
                    "disease_term",
                    "Diagnosis",
                    "Disease or Disorder, Non-Neoplastic",
                    "disease type",
                    "Disorders",
                    "Disease or Disorder",
                    "Disorder",
                    "condition",
                    "disease_type"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Tumor, metastatic",
                    "Metastatic Tumor",
                    "Neoplasm, metastatic",
                    "Metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Tumor",
                    "Tumor, secondary",
                    "Neoplasm, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm",
                    "Neoplasms, NOS",
                    "tumor",
                    "Neoplastic Growth",
                    "Tumor, NOS",
                    "Neoplasia",
                    "Neoplasm, NOS",
                    "Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Recurrence",
                    "Recurrent Cancer",
                    "Recurrent Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C4813",
                "name": "Recurrent Malignant Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C4798",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Unresectable Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127156",
                "name": "Unresectable Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Cancer",
                    "resistant cancer",
                    "clinical resistance"
                ],
                "nci_thesaurus_concept_id": "C120186",
                "name": "Refractory Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C7628"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Neoplasm Recurrence",
                    "Recurrence",
                    "Recurrent Tumor",
                    "Recurrent"
                ],
                "nci_thesaurus_concept_id": "C4798",
                "name": "Recurrent Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Unresectable Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C27359",
                "name": "Unresectable Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Tumor"
                ],
                "nci_thesaurus_concept_id": "C7628",
                "name": "Refractory Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "RTX-240-01",
        "active_sites_count": 2,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C172990",
                        "name": "Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C308",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Agent",
                            "Drug Substance",
                            "Pharmacologic Agent",
                            "Pharmacological Substance",
                            "Drug",
                            "Pharmaceutical Agent",
                            "Pharmaceuticals"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunologic, Immunochemical",
                            "Immunologics",
                            "Biologicals",
                            "Biologics",
                            "Biopharmaceuticals",
                            "Biological Products"
                        ],
                        "nci_thesaurus_concept_id": "C307",
                        "name": "Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunotherapy Agent",
                            "Immune Modulators",
                            "Biomodulators",
                            "BRM",
                            "Immunomodulating Agent",
                            "Immune Mediators",
                            "Immunopotentiators",
                            "Immunomodulators",
                            "Immune Regulators",
                            "Immunotherapeutic Agent",
                            "Biological Response Modifier",
                            "Immunomodulatory Agent"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Part 1: RTX-240 Dose Escalation",
                "description": "Phase 1: RTX-240 monotherapy dose escalation in Solid Tumors",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Part 2: RTX-240 Solid Tumor Expansion",
                "description": "Phase 2: RTX-240 monotherapy dose expansion in Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), and anal cancers",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Part 3: RTX-240 Dose Escalation",
                "description": "Phase 1: RTX-240 monotherapy dose escalation in AML",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Part 4: RTX-240 Plus Pembrolizumab Dose Escalation",
                "description": "Phase 1: RTX-240 dose escalation in combination with Pembrolizumab in Solid Tumors",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2020-04600",
        "why_study_stopped": "Sponsor terminated study during expansion on 11/30/22. RTX-240 was well-tolerated in multiple\r\n    indications, combinations, and dose levels (69pts). No DLTs, related deaths or SAEs were\r\n    reported. RTX-240 cleared circulation rapidly.",
        "brief_summary": "Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 monotherapy or\r\n      in combination of pembrolizumab for the treatment of patients with (1) relapsed/refractory\r\n      R/R or locally advanced solid tumors (Phase 1/2) or (2) R/R Acute Myeloid Leukemia (AML)\r\n      (Phase 1 only).",
        "brief_title": "RTX-240 Monotherapy and in Combination With Pembrolizumab",
        "status_history": [
            {
                "status_date": "2022-11-30T00:00:00.000002",
                "status": "ADMINISTRATIVELY_COMPLETE"
            },
            {
                "status_date": "2022-09-26T00:00:00.000001",
                "status": "CLOSED_TO_ACCRUAL"
            },
            {
                "status_date": "2020-05-01T00:00:00",
                "status": "ACTIVE"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 166,
        "prior_therapy": [],
        "_current_trial_status_sort_order": 8,
        "start_date": "2020-05-06",
        "record_verification_date": "2022-12-01",
        "ctep_id": null,
        "current_trial_status": "Administratively Complete",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Non-Randomized Trial"
        },
        "acronym": null,
        "nci_programs": [],
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2022-11-30",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]